XML 33 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Intangible Assets
 9 Months Ended
Jul. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Note 4. Intangible Assets

Intangible assets consisted of the following:
 July 31, 2024October 31, 2023
(In millions)Gross 
Carrying
Amount		Accumulated
Amortization		Gross 
Carrying
Amount		Accumulated
Amortization
Weighted-Average Amortization Period
(in years)
Intangible assets with definite lives:
Customer relationships$1,123.0 $387.6 $1,099.2 $345.8 19
Composite intangible assets (1)
1,101.5 477.9 1,061.9 424.8 15
Technology660.0 372.7 494.5 335.4 12
Trademarks204.2 87.1 208.9 81.1 15
License and distribution rights and other 48.0 26.5 51.6 28.0 11
3,136.7 $1,351.8 2,916.1 $1,215.1 16
Less: accumulated amortization and translation1,351.8 1,215.1 
Intangible assets with definite lives, net1,784.9 1,701.0 
Intangible assets with indefinite lives, net (2)
1.9 9.3 
Total other intangibles, net$1,786.8 $1,710.3 
(1) Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.
(2) Intangible assets with indefinite lives include technology and trademarks.
Balances include foreign currency translation adjustments.
As of July 31, 2024, the estimate of future amortization expenses for intangible assets with definite lives is as follows:
Fiscal Years:(In millions)
Remainder of 2024$48.6 
2025191.6 
2026184.0 
2027169.7 
2028165.2 
Thereafter1,025.8 
Total remaining amortization for intangible assets with definite lives$1,784.9 
The Company performed its annual impairment assessment in the third quarter of fiscal 2024 and concluded there was no material impairment of goodwill or intangible assets recorded in the nine months ended July 31, 2024. Further information regarding our annual impairment assessment is included in our notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023.